PT932388E - Forma de dosagem e metodo para administracao de farmacos - Google Patents

Forma de dosagem e metodo para administracao de farmacos

Info

Publication number
PT932388E
PT932388E PT97910713T PT97910713T PT932388E PT 932388 E PT932388 E PT 932388E PT 97910713 T PT97910713 T PT 97910713T PT 97910713 T PT97910713 T PT 97910713T PT 932388 E PT932388 E PT 932388E
Authority
PT
Portugal
Prior art keywords
dosage
drugs
administration
lessening
concomitantly
Prior art date
Application number
PT97910713T
Other languages
English (en)
Inventor
Suneel K Gupta
Diane R Guinta
Carol A Christopher
Samuel R Saks
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27363329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT932388(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of PT932388E publication Critical patent/PT932388E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT97910713T 1996-09-30 1997-09-16 Forma de dosagem e metodo para administracao de farmacos PT932388E (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2872696P 1996-09-30 1996-09-30
US3051496P 1996-11-12 1996-11-12
US4412197P 1997-04-22 1997-04-22

Publications (1)

Publication Number Publication Date
PT932388E true PT932388E (pt) 2006-07-31

Family

ID=27363329

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97910713T PT932388E (pt) 1996-09-30 1997-09-16 Forma de dosagem e metodo para administracao de farmacos

Country Status (12)

Country Link
EP (1) EP0932388B1 (pt)
JP (3) JP4714313B2 (pt)
CN (1) CN1231603A (pt)
AT (1) ATE321529T1 (pt)
AU (1) AU4801497A (pt)
CA (1) CA2264852C (pt)
DE (1) DE69735581T2 (pt)
DK (1) DK0932388T5 (pt)
ES (1) ES2262174T3 (pt)
HK (1) HK1127997A1 (pt)
PT (1) PT932388E (pt)
WO (1) WO1998014168A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
WO1998014168A2 (en) * 1996-09-30 1998-04-09 Alza Corporation Dosage form providing a sustained and ascending drug release
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
AU2004200938B2 (en) * 1998-06-03 2006-09-14 Alza Corporation Methods and devices for providing prolonged drug therapy
ES2229783T3 (es) * 1998-06-03 2005-04-16 Alza Corporation Dispositivos para proporcionar una terapia faramaceutica prolongada.
KR100827254B1 (ko) * 1998-06-03 2008-05-07 알자 코포레이션 연장된 약물 치료를 제공하기 위한 방법 및 장치
AU2012232984B2 (en) * 1998-06-03 2015-10-29 Alza Corporation Methods and devices for providing prolonged drug therapy
US6322819B1 (en) 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
EP1126826B3 (en) 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
US6419960B1 (en) 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
US6673367B1 (en) 1998-12-17 2004-01-06 Euro-Celtique, S.A. Controlled/modified release oral methylphenidate formulations
US7083808B2 (en) 1998-12-17 2006-08-01 Euro-Celtique S.A. Controlled/modified release oral methylphenidate formulations
CA2389235C (en) 1999-10-29 2007-07-17 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2283829A1 (en) 2000-10-30 2011-02-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
JP4551089B2 (ja) * 2001-10-29 2010-09-22 マサチューセッツ インスティテュート オブ テクノロジー 三次元印刷により製造されたゼロ次放出プロフィール投薬形態のような徐放投薬形態を製造するためのシステム
JP2010229140A (ja) * 2002-02-22 2010-10-14 Shire Llc 活性物質送達系及び活性物質を保護し投与する方法
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
MX2007001563A (es) * 2004-08-04 2008-03-05 Johnson & Johnson Composicion para liberacion sostenida de farmaco que demuestra un patron de liberacion ascendente del orden cero, metodos para la elaboracion de dicha composicion.
EP2036546B1 (en) 2004-08-23 2018-10-10 PEJO Iserlohn Heilmittel-und Diät-GmbH & Co.KG Psychostimulant containing pharmaceutical composition
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
WO2007109104A2 (en) 2006-03-16 2007-09-27 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US8846100B2 (en) 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
EP1920768A1 (en) * 2006-11-10 2008-05-14 Abbott GmbH & Co. KG Solid dosage form with a film containing an active substance, as well as its method of production
US9226907B2 (en) 2008-02-01 2016-01-05 Abbvie Inc. Extended release hydrocodone acetaminophen and related methods and uses thereof
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP4316488A3 (en) 2011-03-23 2024-02-28 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
CA2880456A1 (en) 2012-08-15 2014-02-20 Tris Pharma, Inc. Methylphenidate extended release chewable tablet
RU2015146324A (ru) 2013-03-29 2017-05-15 Вокхардт Лимитед Фармацевтические композиции модифицированного высвобождения дексметилфенидата или его солей
DE102013014417A1 (de) 2013-08-29 2015-03-05 Klinipharm Gmbh Schwammkollagen umfassende Zubereitungen mit definiertem in vivo-Freisetzungsprofil vor allem im Colon, deren Herstellung und Verwendung
US20170196846A1 (en) * 2014-06-06 2017-07-13 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA2936748C (en) 2014-10-31 2017-08-08 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US11590228B1 (en) 2015-09-08 2023-02-28 Tris Pharma, Inc Extended release amphetamine compositions
US11590081B1 (en) 2017-09-24 2023-02-28 Tris Pharma, Inc Extended release amphetamine tablets
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
US3625214A (en) * 1970-05-18 1971-12-07 Alza Corp Drug-delivery device
DE2336218C3 (de) * 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
EP0094123A3 (en) * 1982-05-06 1984-07-25 THE PROCTER & GAMBLE COMPANY Therapeutic granules
DE3678644D1 (de) * 1985-08-16 1991-05-16 Procter & Gamble Wirkstoffpartikel mit sowohl kontinuierlicher als auch schneller freisetzung.
LU86077A1 (fr) * 1985-09-18 1987-04-02 Pharlyse Sa Nouvelles formes galeniques du verapamil,leur fabrication et medicaments contenant ces nouvelles formes galeniques
DE3822095A1 (de) * 1988-06-30 1990-01-04 Klinge Co Chem Pharm Fab Neue arzneimittelformulierung sowie verfahren zu deren herstellung
SE509029C2 (sv) * 1988-08-16 1998-11-30 Ss Pharmaceutical Co Långtidsverkande diklofenak-natriumpreparat
US4927639A (en) * 1989-02-02 1990-05-22 Warner-Lambert Company Modified release gemfibrozil composition
FI93924C (fi) * 1991-09-17 1995-06-26 Martti Lauri Antero Marvola Menetelmä säädellysti lääkeainetta vapauttavan valmisteen valmistamiseksi
EP0664118B1 (en) * 1991-10-04 1999-08-25 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
ATE234602T1 (de) * 1996-08-16 2003-04-15 Alza Corp Verabreichungsform zur abgabe von steigenden wirkstoffdosen
WO1998014168A2 (en) * 1996-09-30 1998-04-09 Alza Corporation Dosage form providing a sustained and ascending drug release

Also Published As

Publication number Publication date
DK0932388T3 (da) 2006-07-17
ATE321529T1 (de) 2006-04-15
EP0932388B1 (en) 2006-03-29
EP0932388A2 (en) 1999-08-04
AU4801497A (en) 1998-04-24
DE69735581T2 (de) 2007-01-25
HK1127997A1 (en) 2009-10-16
ES2262174T3 (es) 2006-11-16
WO1998014168A2 (en) 1998-04-09
JP2014028854A (ja) 2014-02-13
CN1231603A (zh) 1999-10-13
CA2264852C (en) 2005-11-01
DE69735581D1 (de) 2006-05-18
JP5697893B2 (ja) 2015-04-08
CA2264852A1 (en) 1998-04-09
WO1998014168A3 (en) 1998-07-30
JP2010195822A (ja) 2010-09-09
JP4714313B2 (ja) 2011-06-29
DK0932388T5 (da) 2011-06-27
JP2001501223A (ja) 2001-01-30

Similar Documents

Publication Publication Date Title
PT932388E (pt) Forma de dosagem e metodo para administracao de farmacos
PT957899E (pt) Forma de dosagem para proporcionar um medicamento numa dose crescente
NZ508526A (en) Opioid formulations for treating pain
PT946151E (pt) Forma de dosagem de dose crescente
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
ES2114562T3 (es) Forma de dosificacion para distribucion retardada de farmacos.
DK1032376T3 (da) Anvendelse af benzhydrylsulfinylderivater til behandling af søvnighed af medicinal oprindelse
FI863664A0 (fi) Emulsionskompositioner foer dosering av i vatten svaorloesliga joniserbara hydrofoba laekemedel.
ES2170069T3 (es) 1-alfa-hidroxiprevitamina d para administracion oral.
ATE306266T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
ES2191329T3 (es) Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
ATE292453T1 (de) Antivirale arznei
PT904067E (pt) Dextrometorfan como agente antitussico administrado transdermicamente
DE69812100D1 (de) Adenosin enthaltendes arzneimittel
DK408188D0 (da) Injicerbart middel til kontrolleret frigivelse af opioid-analgetika
EP1690531A3 (en) Dosage form and method for administering drug
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
MD3381G2 (ro) Metodă de tratament al parotiditei cronice la copii
DE59908258D1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
MXPA05001294A (es) Medicamento y proceso para la reduccion del consumo de alcohol y/o tabaco.
RU96102509A (ru) Способ повышения противоопухолевой эффективности в эксперименте